Hologic (HOLX) to Release Earnings on Thursday

Hologic (NASDAQ:HOLX - Get Free Report) is anticipated to release its Q2 2025 earnings data after the market closes on Thursday, May 1st. Analysts expect Hologic to post earnings of $1.02 per share and revenue of $1.00 billion for the quarter. Hologic has set its Q2 2025 guidance at 1.000-1.030 EPS and its FY 2025 guidance at 4.250-4.350 EPS.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, analysts expect Hologic to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Hologic Price Performance

Shares of NASDAQ:HOLX traded up $0.28 during trading on Tuesday, reaching $58.36. The stock had a trading volume of 1,552,009 shares, compared to its average volume of 1,971,891. The stock has a market capitalization of $13.10 billion, a PE ratio of 18.41, a P/E/G ratio of 2.14 and a beta of 0.82. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. Hologic has a 52 week low of $55.89 and a 52 week high of $84.67. The business's 50-day moving average price is $60.78 and its 200 day moving average price is $69.69.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on HOLX shares. Needham & Company LLC cut Hologic from a "buy" rating to a "hold" rating and set a $90.00 price target for the company. in a report on Monday, February 3rd. William Blair reaffirmed an "outperform" rating on shares of Hologic in a report on Thursday, February 6th. Royal Bank of Canada dropped their price target on Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a report on Thursday, February 6th. Evercore ISI lowered their target price on Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a research note on Thursday, February 6th. Finally, Citigroup lowered their target price on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.